ABCSG 31/ALTTO Summary

Randomized, multi-center, open-label, phase-III-study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2-positive primary breast cancer.

Start: 01/2010
Screening-Stop: 06/2010
Coordinating investigator: Gnant, Michael; Vienna
Sample size:
Design:
(Click to enlarge)
ABCSG-31 Design